Four years after a devastating clinical trial failure, Seres Therapeutics seems to have found success. The company announced positive results Monday for its late-stage clinical trial of a microbe-based treatment for C. difficile.
About 11% of patients who got Seres’ drug, a pill made with bacteria, still had a C. difficile recurrence; about 41% of people who did not get the drug saw their infection recur.
About the Author Reprints
